$4.75
0.051.06%
Last update: Aug 20, 11:43 AM
Cytek Biosciences Inc Analyst Ratings
CTKBNASDAQ
Consensus Rating1
Overweight
Highest Price Target1
$7.50
Lowest Price Target1
$3.00
Consensus Price Target1
$5.15
Cytek Biosciences Analyst Ratings and Price Targets | NASDAQ:CTKB | Benzinga
Cytek Biosciences Inc has a consensus price target of $5.15 based on the ratings of 5 analysts. The high is $7.5 issued by Piper Sandler on November 11, 2025. The low is $3 issued by Goldman Sachs on May 12, 2025. The 3 most-recent analyst ratings were released by Stephens & Co., Morgan Stanley, and TD Cowen on May 13, 2026, May 12, 2026, and January 8, 2026, respectively. With an average price target of $5.08 between Stephens & Co., Morgan Stanley, and TD Cowen, there's an implied 7.02% upside for Cytek Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
Morgan Stanley
TD Cowen
Piper Sandler
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Cytek Biosciences
FAQ
What is the target price for Cytek Biosciences (CTKB) stock?
The latest price target for Cytek Biosciences (NASDAQ:CTKB) was reported by Stephens & Co. on May 13, 2026. The analyst firm set a price target for $4.75 expecting CTKB to fall to within 12 months (a possible 0.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
The latest analyst rating for Cytek Biosciences (NASDAQ:CTKB) was provided by Stephens & Co., and Cytek Biosciences maintained their overweight rating.
When was the last upgrade for Cytek Biosciences (CTKB)?
There is no last upgrade for Cytek Biosciences
When was the last downgrade for Cytek Biosciences (CTKB)?
The last downgrade for Cytek Biosciences Inc happened on January 31, 2025 when Goldman Sachs changed their price target from $7 to $4.5 for Cytek Biosciences Inc.
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on May 13, 2026 so you should expect the next rating to be made available sometime around May 13, 2027.
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $5.50 to $4.75. The current price Cytek Biosciences (CTKB) is trading at is $4.75, which is out of the analyst’s predicted range.
